CytomX grants 450,000 options to legal chief

CytomX Therapeutics, Inc. granted Chief Legal Officer Alejandra Carvajal 450,000 stock options on August 3, 2026, with an exercise price of 3.1700 per share and expiration on August 2, 2036.

Rhea-AI Filing Summary

CytomX Therapeutics, Inc. granted Chief Legal Officer Alejandra Carvajal 450,000 stock options on August 3, 2026, with an exercise price of 3.1700 per share and expiration on August 2, 2036. The options vest 25% after one year from August 3, 2026, then monthly over four years, subject to continued service.

On the same date, Carvajal also received 100,000 restricted stock units (RSUs), each settling into one share of common stock upon vesting. These RSUs vest 25% annually each September 15, starting September 15, 2027, contingent on continued service. Following these awards, she holds 450,000 options and 100,000 RSUs directly.

Insider Trade Summary

Grant/Award: 550,000 shares

Grant/Award 2 txns

Insider Carvajal Alejandra

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F3	450,000	$0.00	$0.00
Grant/Award	Common Stock F1, F2	100,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 450,000 contracts (Direct); Common Stock — 100,000 shares (Direct)

Footnotes (3)

1. F1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on September 15 of each year, with the first 25% vesting on September 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such date.
2. F2. Includes 100,000 RSUs.
3. F3. 25% of the shares subject to the option vest on the one-year anniversary measured from August 3, 2026 (the "Vesting Commencement Date"), and 1/48 monthly thereafter such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Key Figures

Stock options granted: 450000.0000 shares Option exercise price: 3.1700 per share Option expiration date: 2036-08-02 +5 more

8 metrics

Stock options granted 450000.0000 shares Options granted to Chief Legal Officer on August 3, 2026

Option exercise price 3.1700 per share Exercise price for 450,000 stock options

Option expiration date 2036-08-02 Expiration date of granted stock options

RSUs granted 100000.0000 units Restricted stock units awarded on August 3, 2026

RSU first vesting date September 15, 2027 First 25% of RSUs vest on this date

Post-award RSU holdings 100000.0000 units Total RSUs held directly after the transaction

Post-award option holdings 450000.0000 shares Total options held directly after the grant

Option vesting commencement August 3, 2026 Date from which option vesting schedule is measured

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy), Vesting Commencement Date, Common Stock

4 terms

restricted stock units ("RSUs") financial

"Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Vesting Commencement Date financial

"measured from August 3, 2026 (the "Vesting Commencement Date")"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

Common Stock financial

"receive one (1) share of Common Stock for each RSU upon vesting"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did CytomX (CTMX) grant to Chief Legal Officer Alejandra Carvajal?

CytomX granted Alejandra Carvajal 450,000 stock options and 100,000 RSUs on August 3, 2026. Each RSU converts into one common share upon vesting, and the options are exercisable for common stock at a fixed price per share.

What are the vesting terms of Alejandra Carvajal’s 100,000 RSUs at CytomX (CTMX)?

Carvajal’s 100,000 RSUs vest 25% annually on September 15 each year, starting September 15, 2027. Vesting is contingent on her continued service to CytomX through each vesting date, after which each RSU settles into one share of common stock.

How do the 450,000 stock options granted to CytomX (CTMX) CLO vest?

The 450,000 stock options vest 25% on the one-year anniversary of August 3, 2026, then 1/48 monthly so they are fully vested on the fourth anniversary. All vesting requires Carvajal’s continued service through each scheduled vesting date.

What is the exercise price and expiration date of Alejandra Carvajal’s CytomX (CTMX) stock options?

The stock options have an exercise price of 3.1700 per share and expire on August 2, 2036. Carvajal can exercise vested options any time before expiration, subject to plan terms and her continued service conditions outlined in the award.

Were Alejandra Carvajal’s CytomX (CTMX) equity grants made under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked, so these equity awards are not reported as being made under a Rule 10b5-1 trading plan. They are characterized as grant/award acquisitions rather than open-market transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 07:33 PM Accepted by SEC EDGAR 08/05/2026 - 07:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carvajal Alejandra

(Last) (First) (Middle)

C/O CYTOMX THERAPEUTICS, INC.

151 OYSTER POINT BLVD., STE. 400

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CytomX Therapeutics, Inc. [ CTMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		A		100,000(1)	A	$0	100,000(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.17	08/03/2026		A		450,000		(3)	08/02/2036	Common Stock	450,000	$0	450,000	D

Explanation of Responses:

1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on September 15 of each year, with the first 25% vesting on September 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such date.

2. Includes 100,000 RSUs.

3. 25% of the shares subject to the option vest on the one-year anniversary measured from August 3, 2026 (the "Vesting Commencement Date"), and 1/48 monthly thereafter such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

	/s/ Christopher Ogden, as Attorney-in-Fact for Alejandra Carvajal	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)